COMP <GO>
HIMS vs JNJ // NET PROFIT MARGIN
Hims & Hers Health Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HIMS 3
— JNJ 10
▲ NET PROFIT MARGIN LEADER: JNJ
LAST: $27.68 (-6.71%) • MKT CAP: $6.92B
net-margins
5.50%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HIMS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HIMS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.80% | 67.90% | +5.90 | HIMS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 25.50% | -17.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.7x | 18.5x | +19.20 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.81% | 2.97% | -0.16 | JNJ | /fcf-yield <GO> |
| Operating Margin | 4.50% | 34.70% | -30.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 5.50% | 28.50% | -23.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 59.00% | 6.00% | +53.00 | HIMS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.95 | 5.59 | -1.64 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | HIMS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.9 | 60.4 | -15.44 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.08 | -0.03 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.3x | 23.0x | +22.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.92B | $662.49B | -$655.57B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HIMS REV | JNJ REV | HIMS GROSS % | JNJ GROSS % | HIMS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.35B | $94.19B | 73.8% | 67.9% | $194.4M | $19.70B |
| FY 2024 | $1.48B | $88.82B | 79.5% | 69.1% | $184.6M | $19.84B |
| FY 2023 | $872.0M | $85.16B | 44.0% | 44.0% | $34.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HIMS // BETA 1.05
JNJ // BETA 1.08